Atalanta Therapeutics Closes Oversubscribed $97 Million Series B Financing to Advance Two RNAi Therapies for CNS Diseases to Clinical Trials
– IND submissions planned in 2025 for first two programs within leading portfolio of di-siRNA therapies – – Series B funds will support progressing programs for KCNT1-related epilepsy and Huntington’s disease through clinical proof-of-concept – January…